Skip to main content
Signal8

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

$BLRXPress releaseMay 27, 2026, 7:00 AM ETRead the release

BioLineRx reported Q1 2026 revenue of $0.5 million, driven by royalties from APHEXDA sales, and a net loss of $2.6 million. The company highlighted a key milestone: the first patient was dosed in the Phase 1/2a clinical trial for GLIX1 in glioblastoma, with two additional abstracts accepted for ASCO.

Key figures

Eps
0
Revenue
477000
Revenue Yoy
87%
Net loss
2588000
Rd expenses
2528000
Apexda sales
2700000
Operating loss
3004000
Royalty revenue
477000
G and a expenses
858000
Cash and equivalents
17400000

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    BLRX: BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update — AI Analysis | Signal8